{"id":534,"date":"2026-10-09T05:55:08","date_gmt":"2026-10-08T21:55:08","guid":{"rendered":"http:\/\/www.thongtinkinhte.com\/blog\/?p=534"},"modified":"2026-10-09T05:55:08","modified_gmt":"2026-10-08T21:55:08","slug":"how-to-choose-the-right-urology-device-for-prostate-problems-4a62-c4b8c0","status":"publish","type":"post","link":"http:\/\/www.thongtinkinhte.com\/blog\/2026\/10\/09\/how-to-choose-the-right-urology-device-for-prostate-problems-4a62-c4b8c0\/","title":{"rendered":"How to choose the right urology device for prostate problems?"},"content":{"rendered":"

If you\u2019re reading this, chances are you\u2019re either a urologist, a practice manager, or a hospital procurement lead navigating the overwhelming landscape of urology devices for prostate problems\u2014and trust me, I\u2019ve been in your shoes. For the past 12 years, I\u2019ve worked hands-on with clinicians to source, test, and support urology devices for prostate-related conditions, from benign prostatic hyperplasia (BPH) to prostate cancer. I\u2019ve sat through procurement meetings where teams confused \u201cnewest\u201d with \u201cmost effective,\u201d watched practices overspend on devices that didn\u2019t fit their patient volume, and even heard from clinicians who abandoned a tool after six months because it added more work to their already overloaded schedules. Choosing the right urology device isn\u2019t just about checking a box for your clinic or hospital\u2014it\u2019s about improving patient outcomes, streamlining your team\u2019s workflow, and making care more accessible for the men who rely on you. Today, I want to break down the key factors we\u2019ve learned along the way to help you make a choice that works for everyone. Urology Device<\/a><\/p>\n

<\/p>\n

Let\u2019s start with the most common prostate issue clinicians treat: BPH, or enlarged prostate. It\u2019s a condition that affects 50% of men by age 50 and up to 90% by age 80, according to the American Urological Association (AUA). When I first got into this field, the go-to treatment was transurethral resection of the prostate (TURP), a procedure that\u2019s been around since the 1920s. But over the last two decades, we\u2019ve seen a surge in minimally invasive (MI) devices that target specific areas of the prostate without the large incisions or lengthy recovery times of traditional surgery. The question is: which of these MI devices is right for your practice?<\/p>\n

First, you need to ground your choice in your patient population. Let\u2019s say you work in a community clinic where most patients are 70+ with smaller-to-moderate prostates (30\u201380 grams) and limited mobility. For these patients, a water-induced thermotherapy device might be ideal. This tool uses heated water to gently shrink prostate tissue, takes about an hour in the office, and requires no general anesthesia\u2014something that\u2019s huge for older patients who might be at higher risk for surgery complications. On the other hand, if you\u2019re in a tertiary care center that sees younger, more active patients with larger prostates (over 80 grams), a minimally invasive lift procedure that holds excess tissue out of the urethra might be a better fit. Patients who opt for lifts often return to their normal activities in a few days, which is a big selling point for men who don\u2019t want to take time off work or skip their weekend hobbies.<\/p>\n

I\u2019ve seen practices make the mistake of buying a device that works for a neighboring clinic\u2019s patient base but doesn\u2019t align with their own. Last year, we worked with a small clinic in rural Ohio that purchased a laser ablation device specifically for large prostates because a nearby academic medical center recommended it. But their average patient\u2019s prostate was only 45 grams, and the laser device required specialized training that their three-person urology team couldn\u2019t spare. Six months later, they were using the device less than once a month and had spent $120,000 on equipment they barely touched. That\u2019s why step one: audit your patient data. Pull the last two years of prostate cases, note the average prostate size of your BPH patients, their age range, and any comorbidities (like diabetes or heart disease) that might affect which procedures they can safely undergo.<\/p>\n

Next, workflow and team compatibility are non-negotiable. Urology teams are stretched thin\u2014clinicians have back-to-back appointments, medical assistants handle pre-op and post-op checks, and practice managers are balancing budgets. A device that\u2019s too complex, requires extra supplies, or adds 20 minutes to each procedure might look great on paper, but it will burn out your team in no time. Let\u2019s compare two common BPH devices: a needle-based water vapor thermal therapy (WVTT) and a robotic-assisted transurethral resection (TURP) system. The WVTT device is pre-loaded with single-use cartridges, so once the clinician inserts the device into the urethra, it takes three 12-minute cycles to deliver the vapor, with minimal setup time. It doesn\u2019t require a specialized operating room\u2014you can do it in your standard urology procedure room. The robotic TURP system, by contrast, requires a dedicated OR, a circulating nurse trained in robotic equipment, and a setup that can take 45 minutes before the first patient. For a clinic that does 10\u201315 BPH procedures a month, WVTT will cut down on OR wait times and reduce staff overtime, whereas robotic TURP only makes sense if you\u2019re doing 20+ procedures monthly or have a high volume of complex cases.<\/p>\n

I learned this lesson early on from a client in Chicago. Their team had always used traditional TURP in their OR, but they noticed that 60% of their BPH patients opted for office-based procedures when given the choice. They purchased a WVTT device, and within three months, their BPH procedure volume increased by 30%\u2014because patients preferred the office setting, and the team didn\u2019t have to coordinate with OR scheduling or anesthesiologists as much. The key here is to talk to the people who will actually use the device, not just the practice manager signing the check. Ask your clinicians: How much time does this device take to set up? Does it require new training that pulls me away from patient care? Ask your medical assistants: Does this device add extra steps to pre-op or post-op care that I didn\u2019t plan for? You might be surprised how much a small detail\u2014like a device that has a large, heavy console vs. a portable unit that rolls easily between rooms\u2014can impact daily operations.<\/p>\n

Then there\u2019s cost, but not just the upfront sticker price. Too many procurement teams fixate on the initial cost of a device without accounting for long-term expenses, like disposables, maintenance, and reprocessing. Let\u2019s use another example: a bipolar TURP resectoscope vs. a microwave thermotherapy device. The resectoscope costs around $15,000 upfront, and each procedure uses $800 worth of disposable electrodes and fluids. The microwave thermotherapy device costs $80,000 upfront, but each procedure uses only $200 worth of disposables. If you do 50 BPH procedures a year, the resectoscope will cost you $40,000 in disposables annually, while the thermotherapy device will cost $10,000. That means the thermotherapy device pays for itself in two and a half years, not to mention the lower risk of complications like bleeding that require additional follow-up visits, which add more indirect costs.<\/p>\n

Also, don\u2019t forget about maintenance and support. If a device breaks down, how quickly can a technician come to fix it? Does the manufacturer offer on-site training for your team, or do you have to send them to a training center 3 hours away? When I\u2019m advising a practice, I always ask for the total cost of ownership over five years, not just the upfront price. That includes disposable costs, service contracts, training fees, and even the cost of downtime if the device is out of order. We recently worked with a urology group in Florida that purchased a foreign-made laser device for prostate ablation. The upfront cost was $20,000 less than a domestic brand, but when the device broke 18 months later, the manufacturer took four weeks to send a replacement part\u2014meaning their team lost 12 days of procedure time and had to refer patients to a nearby practice, which hurt their revenue and patient satisfaction. Domestic suppliers might have a slightly higher upfront cost, but faster support and lower shipping times can save you thousands in the long run.<\/p>\n

Now, what if we\u2019re talking about devices for prostate cancer, not just BPH? Prostate cancer is the second most common cancer in men worldwide, and treatment ranges from active surveillance to radical surgery or radiation. For early-stage, low-risk prostate cancer, focal therapy devices\u2014 which target only the cancerous portion of the prostate instead of the entire gland\u2014are becoming increasingly popular. These devices use ultrasound, cryotherapy, or heat to destroy cancer cells while sparing healthy tissue, which means fewer side effects like incontinence or erectile dysfunction compared to radical prostatectomy.<\/p>\n

When choosing a focal therapy device, the same rules apply: align with your patient population and clinical expertise. If your practice already has experience with ultrasound imaging, an ultrasound-guided focal ablation device might be a natural fit. If you work with oncologists who specialize in radiation, a brachytherapy device that delivers radioactive seeds directly to the cancer site could integrate well with your existing care pathways. Again, workflow is key: focal therapy can often be done in an office setting, reducing the need for hospital stays, but requires precise imaging to target the cancer accurately. If your team doesn\u2019t have access to real-time MRI for prostate imaging, a device that uses ultrasound guidance might be more practical than one that requires MRI, even if the MRI-guided device has slightly higher success rates.<\/p>\n

I also want to touch on patient outcomes and evidence. No device should be chosen based on marketing alone\u2014you need to look at peer-reviewed data, clinical trial results, and real-world performance from practices similar to yours. For example, a 5-year study published in the Journal of Urology<\/em> found that water vapor thermal therapy for BPH had a 92% patient satisfaction rate and only a 5% re-intervention rate, which is better than traditional TURP in many cases. But another study in the same journal found that laser ablation had a lower re-intervention rate for very large prostates, so that data can help you match the device to your patient\u2019s prostate size.<\/p>\n

Avoid falling for the \u201clatest and greatest\u201d hype. A new device might have flashy marketing, but if there\u2019s only a small, 100-patient trial behind it, it might not have the long-term data you need to feel confident that it works. We work with clinicians to prioritize devices that have at least 3\u20135 years of real-world evidence, and that have been used by practices with similar patient volumes and demographics to ours.<\/p>\n

At the end of the day, choosing the right urology device for prostate problems is about balance: balancing patient needs, team workflow, budget, and clinical evidence. There\u2019s no one-size-fits-all solution, but taking the time to audit your patient data, talk to your team, calculate total cost of ownership, and review clinical data will help you make a choice that serves your practice and your patients for years to come.<\/p>\n

<\/p>\n

If you\u2019re ready to start evaluating devices for your practice, our team has worked with hundreds of urology clinics to assess their needs, test devices, and find solutions that fit their unique workflows. We offer free clinical consultations, personalized device demonstrations, and transparent pricing with no hidden fees. Whether you\u2019re looking for BPH treatment devices, prostate cancer focal therapy tools, or support for post-procedure care, we\u2019re here to help you navigate the process without the stress.<\/p>\n

Urology Device<\/a> References:
\nAmerican Urological Association. (2023). AUA Guideline for the Management of Benign Prostatic Hyperplasia. Journal of Urology, 210(3), 481\u2013490.
\nEmmott, L. J., et al. (2021). 5-Year Outcomes of Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia. Journal of Urology, 205(4), 1123\u20131129.
\nPorcaro, A. B., et al. (2022). Focal Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis. European Urology, 81(2), 187\u2013196.
\nUryvaev, A., et al. (2020). Total Cost of Ownership of Minimally Invasive Procedures for Benign Prostatic Hyperplasia. Urology Practice, 7(5), 452\u2013458.<\/p>\n

\n

Galaxymed Technology Co., Ltd.<\/a>
As one of the most professional urology device suppliers in China, we’re featured by good quality products and in-time service. Please rest assured to buy hospital grade urology device made in China here and get quotation from our factory. Also, small qty acceptable.
Address: 88 Dongchang Road, Suzhou Industrial Park, Suzhou City, Jiangsu Province, China
E-mail: Sales@galaxymed.com.cn
WebSite: https:\/\/www.galaxy-medic.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

If you\u2019re reading this, chances are you\u2019re either a urologist, a practice manager, or a hospital … How to choose the right urology device for prostate problems?<\/span>Read more<\/a><\/p>\n","protected":false},"author":131,"featured_media":534,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[497],"class_list":["post-534","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-industry","tag-urology-device-4245-c4f84b"],"_links":{"self":[{"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/posts\/534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/comments?post=534"}],"version-history":[{"count":0,"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/posts\/534\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/posts\/534"}],"wp:attachment":[{"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/media?parent=534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/categories?post=534"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.thongtinkinhte.com\/blog\/wp-json\/wp\/v2\/tags?post=534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}